Immunic remains committed to developing its MS drug, vidofludimus calcium, despite a Phase II trial not meeting its primary endpoint. Positive results include reduced brain volume loss and disability worsening risk, particularly in primary progressive MS patients. The drug also showed safety and tolerability.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing